Table 4.

CIBIC+ scores at week 24 – MMRM¹ (ITT population)

Subject group	Treatment group	Number2	LSM	SE	Treatment comparison
					difference3	95% CI	P
APOE ε4 negative	placebo	63	4.2	0.14	_	_	_
	2 mg RSG XR	71	4.2	0.12	0.1	−0.3,0.4	0.663
	8 mg RSG XR	66	4.1	0.11	0.0	−0.4, 0.3	0.891
	10 mgdonepezil	28	3.9	0.22	−0.2	−0.7,0.3	0.4144
All except ε4/ε4	placebo	117	4.3	0.10	-	-	-
	2 mg RSG XR	117	4.3	0.10	0.0	−0.3,0.3	0.913
	8 mg RSG XR	114	4.1	0.10	−0.1	−0.4,0.1	0.276
	10 mgdonepezil	49	3.8	0.17	−0.5	−0.8,-0.1	0.0254
Full population	placebo	131	4.3	0.09	_	_	_
	2 mg RSG XR	133	4.3	0.09	0.0	−0.2,0.3	0.939
	8 mg RSG XR	127	4.2	0.10	−0.1	−0.4,0.1	0.307
	10 mgdonepezil	56	3.8	0.16	−0.5	−0.8,-0.1	0.0094

The CIBIC+ rates global functioning with scores ranging from 1 (markedly improved) to 7 (markedly worse). A score of 4 represents no change and negative treatment differences reflect benefit in the active treatment over placebo. LSM = Least squares mean; SE = standard error for LSM.

¹Model includes terms for country group, visit, APOE ε4 gene dose, treatment, baseline body mass index, baseline MMSE score, baseline MMSE score by visit, and treatment by visit.

²Number of subjects with a CIBIC+ score at week 24.

³Difference (active treatment minus placebo).

⁴Unadjusted p.